Mobile-ECG screening in rural pharmacies: rates of atrial fibrillation and associated risk factors.
Atrial fibrillation
Community screening
ECG
Health tracking
Mobile health
Patient engagement
Rural health
Journal
Heart & lung : the journal of critical care
ISSN: 1527-3288
Titre abrégé: Heart Lung
Pays: United States
ID NLM: 0330057
Informations de publication
Date de publication:
Historique:
received:
22
08
2019
revised:
07
01
2020
accepted:
08
01
2020
pubmed:
6
2
2020
medline:
22
12
2020
entrez:
5
2
2020
Statut:
ppublish
Résumé
Atrial fibrillation (AFib) is a growing health concern, affecting more than 40 million patients worldwide and increasing stroke risk by five times. Community screening initiatives in rural healthcare establishments are becoming more feasible with the development of innovative, mobile-ECG (mECG) technology. The purpose of this research was to characterize increased rates of stroke risk factors and to determine AFib incidence in rural, pharmacy settings. The researchers examined the prevalence of risk factors associated with AFib and calculated CHA₂DS₂-VASc stroke risk scores in a previously undiagnosed AFib community sample of 250 participants. Eligible participants at two rural pharmacies were administered a 1-lead mECG reading. Participants were then asked to complete questionnaires on demographic and medical history information. All participants were given educational materials on AFib and medical referrals when indicated. Prevalence rates of six, known independent stroke risk factors (CHA₂DS₂-VASc scores: (2.68 ± 1.35)) were significantly higher in the study sample than reported national US averages. Screening via mECG indicated preliminary AFib rates of approximately 4%; however, upon independent adjudication of the readings from three electrophysiologists AFib prevalence ranged between 1% and 8%. Collectively, an alarming rate of untreated stroke risk in a rural pharmacy sample was identified by the researchers utilizing mECG technology. These results suggest potential value to the use of mECG technology to screen for AFib in at-risk communities.
Identifiants
pubmed: 32014313
pii: S0147-9563(20)30004-2
doi: 10.1016/j.hrtlng.2020.01.004
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
377-380Informations de copyright
Published by Elsevier Inc.
Déclaration de conflit d'intérêts
Declaration of Competing Interest Samuel F. Sears, PhD: Honoraria/Consulting Fees: Medtronic, Boston Scientific, Abbott, Zoll Medical; Research Grants: Medtronic, Zoll Medical. All funds are directed to East Carolina University. Ashley Burch, PhD: Research Grants: Zoll Medical. J.P. Mounsey, MD: Honoraria/Consulting Fees: Medtronic, Boston Scientific, Janssen. No conflicts of interest to report for other authors.